India is unlikely to clear Sanofi Pasteur ’s dengue vaccine, Dengvaxia, in a hurry and the government would prefer a “cautious” approach given certain safety concerns in young children and the risk of indiscriminate use of the product in the country, among other issues.
Dr Soumya Swaminathan, secretary, department of health research, Ministry of Health and Family Welfare and director general, Indian Council for...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
